Cargando…
Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including nausea, vomiting, and diarrhea. A growing body of evidence indicates that bacteria β-glucuronidase (GUS), an enzyme expre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593678/ https://www.ncbi.nlm.nih.gov/pubmed/34795594 http://dx.doi.org/10.3389/fphar.2021.774560 |
_version_ | 1784599800511987712 |
---|---|
author | Yue, Bei Gao, Ruiyang Lv, Cheng Yu, Zhilun Wang, Hao Geng, Xiaolong Wang, Zhengtao Dou, Wei |
author_facet | Yue, Bei Gao, Ruiyang Lv, Cheng Yu, Zhilun Wang, Hao Geng, Xiaolong Wang, Zhengtao Dou, Wei |
author_sort | Yue, Bei |
collection | PubMed |
description | Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including nausea, vomiting, and diarrhea. A growing body of evidence indicates that bacteria β-glucuronidase (GUS), an enzyme expressed by intestinal microbiota, converts the inactive CPT11 metabolite SN38G to the active metabolite SN38 to ultimately induce intestinal mucositis. We sought to explore the potential efficacy and underlying mechanisms of berberine on CPT11-induced mucositis. Our study showed that berberine (50 mg/kg; i. g.) mitigated the CPT11-induced loss of mucosal architecture, ulceration, and neutrophil infiltration. Meanwhile, berberine improved mucosal barrier function by increasing the number of globlet cells, protecting trans-endothelial electrical resistance (TEER), reducing permeability and increasing tight junction proteins expression. LC-MS analysis showed that berberine decreased the content of SN38 in feces, which correlated with decreases in both GUS activity and GUS-producing bacteria. Further molecular docking and Lineweaver-Burk plots analyses suggested that berberine functions as a potential non-competitive inhibitor against GUS enzyme. Of note, berberine maintained the anti-tumor efficacy of CPT11 in a tumor xenograft model while abrogating the intestinal toxicity of CPT11. Overall, we identified for the first time the remission effects of berberine on intestinal mucositis induced by CPT11 without impairing the anti-colorectal cancer efficacy of CPT11 partially via inhibiting bacterial GUS enzyme. |
format | Online Article Text |
id | pubmed-8593678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85936782021-11-17 Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase Yue, Bei Gao, Ruiyang Lv, Cheng Yu, Zhilun Wang, Hao Geng, Xiaolong Wang, Zhengtao Dou, Wei Front Pharmacol Pharmacology Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including nausea, vomiting, and diarrhea. A growing body of evidence indicates that bacteria β-glucuronidase (GUS), an enzyme expressed by intestinal microbiota, converts the inactive CPT11 metabolite SN38G to the active metabolite SN38 to ultimately induce intestinal mucositis. We sought to explore the potential efficacy and underlying mechanisms of berberine on CPT11-induced mucositis. Our study showed that berberine (50 mg/kg; i. g.) mitigated the CPT11-induced loss of mucosal architecture, ulceration, and neutrophil infiltration. Meanwhile, berberine improved mucosal barrier function by increasing the number of globlet cells, protecting trans-endothelial electrical resistance (TEER), reducing permeability and increasing tight junction proteins expression. LC-MS analysis showed that berberine decreased the content of SN38 in feces, which correlated with decreases in both GUS activity and GUS-producing bacteria. Further molecular docking and Lineweaver-Burk plots analyses suggested that berberine functions as a potential non-competitive inhibitor against GUS enzyme. Of note, berberine maintained the anti-tumor efficacy of CPT11 in a tumor xenograft model while abrogating the intestinal toxicity of CPT11. Overall, we identified for the first time the remission effects of berberine on intestinal mucositis induced by CPT11 without impairing the anti-colorectal cancer efficacy of CPT11 partially via inhibiting bacterial GUS enzyme. Frontiers Media S.A. 2021-11-02 /pmc/articles/PMC8593678/ /pubmed/34795594 http://dx.doi.org/10.3389/fphar.2021.774560 Text en Copyright © 2021 Yue, Gao, Lv, Yu, Wang, Geng, Wang and Dou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yue, Bei Gao, Ruiyang Lv, Cheng Yu, Zhilun Wang, Hao Geng, Xiaolong Wang, Zhengtao Dou, Wei Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase |
title | Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase |
title_full | Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase |
title_fullStr | Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase |
title_full_unstemmed | Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase |
title_short | Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase |
title_sort | berberine improves irinotecan-induced intestinal mucositis without impairing the anti-colorectal cancer efficacy of irinotecan by inhibiting bacterial β-glucuronidase |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593678/ https://www.ncbi.nlm.nih.gov/pubmed/34795594 http://dx.doi.org/10.3389/fphar.2021.774560 |
work_keys_str_mv | AT yuebei berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase AT gaoruiyang berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase AT lvcheng berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase AT yuzhilun berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase AT wanghao berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase AT gengxiaolong berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase AT wangzhengtao berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase AT douwei berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase |